Angiostatic Proteins: Proteins that specifically inhibit the growth of new blood vessels (ANGIOGENESIS, PHYSIOLOGIC).Angiogenesis Inhibitors: Agents and endogenous substances that antagonize or inhibit the development of new blood vessels.Neovascularization, Pathologic: A pathologic process consisting of the proliferation of blood vessels in abnormal tissues or in abnormal positions.Chemokine CXCL10: A CXC chemokine that is induced by GAMMA-INTERFERON and is chemotactic for MONOCYTES and T-LYMPHOCYTES. It has specificity for the CXCR3 RECEPTOR.Angiostatins: Circulating 38-kDa proteins that are internal peptide fragments of PLASMINOGEN. The name derives from the fact that they are potent ANGIOGENESIS INHIBITORS. Angiostatins contain four KRINGLE DOMAINS which are associated with their potent angiostatic activity.Endostatins: Angiostatic proteins that are formed from proteolytic cleavage of COLLAGEN TYPE XVIII.Platelet Factor 4: A CXC chemokine that is found in the alpha granules of PLATELETS. The protein has a molecular size of 7800 kDa and can occur as a monomer, a dimer or a tetramer depending upon its concentration in solution. Platelet factor 4 has a high affinity for HEPARIN and is often found complexed with GLYCOPROTEINS such as PROTEIN C.Receptors, CXCR3: CXCR receptors that are expressed on the surface of a number of cell types, including T-LYMPHOCYTES; NK CELLS; DENDRITIC CELLS; and a subset of B-LYMPHOCYTES. The receptors are activated by CHEMOKINE CXCL9; CHEMOKINE CXCL10; and CHEMOKINE CXCL11.Pregnadienediols: Doubly unsaturated pregnane derivatives with two hydroxy groups substituted anywhere on the rings or side chains.Chemokine CXCL11: A CXC chemokine that is induced by GAMMA-INTERFERON. It is a chemotactic factor for activated T-LYMPHOCYTES and has specificity for the CXCR3 RECEPTOR.Thrombospondin 1: An extracellular matrix glycoprotein from platelets and a variety of normal and transformed cells of both mesenchymal and epithelial origin. Thrombospondin-1 is believed to play a role in cell migration and proliferation, during embryogenesis and wound repair. Also, it has been studied for its use as a potential regulator of tumor growth and metastasis.

Platelets release CXCL4L1, a nonallelic variant of the chemokine platelet factor-4/CXCL4 and potent inhibitor of angiogenesis. (1/25)

Platelet factor-4 (PF-4)/CXCL4 was the first chemokine described to inhibit neovascularization. Here, the product of the nonallelic variant gene of CXCL4, PF-4var1/PF-4alt, designated CXCL4L1, was isolated for the first time from thrombin-stimulated human platelets and purified to homogeneity. Although secreted CXCL4 and CXCL4L1 differ in only three amino acids, CXCL4L1 was more potent in inhibiting chemotaxis of human microvascular endothelial cells toward interleukin-8 (IL-8)/CXCL8 or basic fibroblast growth factor (bFGF). In vivo, CXCL4L1 was also more effective than CXCL4 in inhibiting bFGF-induced angiogenesis in rat corneas. Thus, activated platelets release CXCL4L1, a potent regulator of endothelial cell biology, which affects angiogenesis and vascular diseases.  (+info)

BMP-1/Tolloid-like metalloproteases process endorepellin, the angiostatic C-terminal fragment of perlecan. (2/25)

Endorepellin, the C-terminal domain of the heparan sulfate proteoglycan perlecan, possesses angiostatic activity. The terminal laminin-like globular (LG3) domain of endorepellin appears to possess most of the biological activity on endothelial cells. LG3 protein has been detected in the urine of patients with end-stage renal disease and in the amniotic fluid of pregnant women with premature rupture of fetal membranes. These findings suggest that proteolytic processing of endorepellin and the generation of LG3 might have biological significance. In this study, we have identified specific enzymes of the bone morphogenetic protein-1 (BMP-1)/Tolloid family of metalloproteases that cleave LG3 from recombinant endorepellin at the physiologically relevant site and that cleave LG3 from endogenous perlecan in cultured mouse and human cells. The BMP-1/Tolloid family of metalloproteases is thereby implicated in the processing of a major basement membrane proteoglycan and in the liberation of an anti-angiogenic factor. Using molecular modeling, site-directed mutagenesis and angiogenic assays, we further demonstrate that LG3 activity requires specific amino acids involved in Ca(2+) coordination.  (+info)

Angiostatic peptides use plasma fibronectin to home to angiogenic vasculature. (3/25)

A group of angiogenesis inhibitors are derived from fragments of extracellular matrix or blood proteins. Endostatin, antithrombin, and anastellin are members of this group of substances. The plasma adhesion proteins fibronectin and vitronectin serve as cofactors for these three antiangiogenic proteins. Anginex is a synthetic 33-amino acid peptide that was originally modeled to reproduce the beta-sheet structure of antiangiogenic proteins. Here, we show that anginex initiates fibronectin polymerization and is inactive in mice that lack plasma fibronectin. Anginex shares these characteristics with anastellin. Fluorescein-labeled anginex and anastellin specifically localized in angiogenic vessels in vivo. This localization was dependent on plasma fibronectin and inhibited by an Arg-Gly-Asp peptide. Thus, anginex shares with several physiological angiogenesis inhibitors a dependence on plasma adhesion proteins. The role of the adhesion protein interaction apparently is to form integrin-binding complexes that deliver the antiangiogenic proteins to sites of angiogenesis. This functional convergence of several antiangiogenic factors has important implications for antiangiogenic therapies.  (+info)

Identification of CD36 molecular features required for its in vitro angiostatic activity. (4/25)

Thrombospondin-1 (TSP-1), a natural inhibitor of angiogenesis, acts directly on endothelial cells (EC) via CD36 to inhibit their migration and morphogenesis induced by basic fibroblast growth factor. Here we show that CD36 triggered by TSP-1 inhibits in vitro angiogenesis stimulated by vascular endothelial growth factor-A (VEGF-A). To demonstrate that the TSP-1 inhibitory signal was mediated by CD36, we transduced CD36 in CD36-deficient endothelial cells. Both TSP-1 and the agonist anti-CD36 mAb SMO, which mimics TSP-1 activity, reduced the VEGF-A165-induced migration and sprouting of CD36-ECs. To address the mechanisms by which CD36 may exert its angiostatic function, we investigated the functional components of the C-terminal cytoplasmic tail by site-directed mutagenesis. Our results indicate that C464, R467, and K469 of CD36 are required for the inhibitory activity of TSP-1. In contrast, point mutation of C466 did not alter TSP-1 ability to inhibit EC migration and sprouting. Moreover, we show that activation of CD36 by TSP-1 down-modulates the VEGF receptor-2 (VEGFR-2) and p38 mitogen-associated protein kinase phosphorylation induced by VEGF-A165, and this effect was specifically abolished by point mutation at C464. These results identify specific amino acids of the C-terminal cytoplasmic tail of CD36 crucial for the in vitro angiostatic activity of TSP-1 and extend our knowledge of regulation of VEGFR-2-mediated biological activities on ECs.  (+info)

T2-TrpRS inhibits preretinal neovascularization and enhances physiological vascular regrowth in OIR as assessed by a new method of quantification. (5/25)

PURPOSE: A carboxyl-terminal fragment of tryptophan tRNA synthetase (T2-TrpRS) has demonstrated potent angiostatic activity during retinal developmental neovascularization in vivo. The effects of T2-TrpRS on pathologic neovascularization were tested and compared with a potent VEGF antagonist using the mouse model of oxygen-induced retinopathy (OIR). METHODS: C57BL/6J mice were transiently exposed to hyperoxic conditions (75% O2) between postnatal day 7 (P7) and P12 and then returned to room air. Retinas were isolated, blood vessels stained with isolectin Griffonia simplicifolia, images of retinal whole-mounts acquired, and the area of vascular obliteration and extent of preretinal neovascularization quantified. This method was compared to the commonly used method of OIR quantification in which the number of pre-inner limiting membrane (ILM) nuclei is counted in serial sections of whole eyes. To assess the angiostatic activity of T2-TrpRS, mice were injected intravitreally at P12 with either T2-TrpRS, a VEGF aptamer, or vehicle (PBS) alone, and the effects on area of obliteration and on preretinal neovascular tuft formation were assessed. RESULTS: Using a modified method of quantification in the mouse OIR model based on images of isolectin-stained retinal wholemounts, we were able to assess reliably and consistently both vascular obliteration and preretinal neovascular tuft formation in the same specimen. T2-TrpRS demonstrated potent angiostatic activity, reducing the appearance of pathologic neovascular tufts by up to 90%. Surprisingly, T2-TrpRS also enhanced physiological revascularization of the obliterated retinal vasculature, reducing these areas by up to 60% compared with PBS-injected eyes. In contrast, the VEGF antagonist, while similarly reducing preretinal neovascular tuft formation, did not enhance revascularization of the obliterated areas. CONCLUSIONS: Use of a rapid, quantifiable method to assess the effect of T2-TrpRS on retinal angiogenesis in the OIR model demonstrates the importance of a quantification system that permits simultaneous analysis of a drug's effect on vascular obliteration as well as on preretinal neovascularization. The results obtained using this method suggest enhanced clinical value for compounds such as T2-TrpRS that not only inhibit pathologic neovascularization, but also facilitate physiological revascularization of ischemic tissue.  (+info)

Endorepellin, the C-terminal angiostatic module of perlecan, enhances collagen-platelet responses via the alpha2beta1-integrin receptor. (6/25)

Endorepellin, a C-terminal fragment of the vascular basement membrane proteoglycan perlecan, inhibits angiogenesis via the alpha2beta1-integrin receptor. Because this integrin is also implicated in platelet-collagen responses and because endorepellin or its fragments are generated in response to injury and inflammation, we hypothesized that endorepellin could also affect platelet biology. We discovered that endorepellin supported alpha2beta1-dependent platelet adhesion, without appreciably activating or aggregating platelets. Notably, endorepellin enhanced collagen-evoked responses in platelets, in a src kinase-dependent fashion, and enhanced the collagen-inhibitory effect of an alpha2beta1-integrin function-blocking antibody. Collectively, these results suggest that endorepellin/alpha2beta1-integrin interaction and effects are specific and dependent on cell type, differ from those emanated by exposure to collagen, and may be due to cellular differences in alpha2beta1-integrin activation/ligand affinity state. These studies also suggest a heretofore unrecognized role for angiostatic basement membrane fragments in platelet biology.  (+info)

Clinical implications of angiogenesis in cancers. (7/25)

Angiogenesis plays an important role in the growth and progression of cancer. The regulation of tumor angiogenesis depends on a net balance of angiogenic factors and antiangiogenic factors, which are secreted by both tumor cells and host-infiltrating cells. Numerous studies have indicated that assessment of angiogenic activity by either microvessel density or expression of angiogenic factors in cancer can provide prognostic information independent of conventional clinicopathological factors such as tumor staging. Some studies also suggested that assessment of tumor angiogenesis may predict cancer response to chemotherapy or radiotherapy. However, the most important clinical implication of tumor angiogenesis is the development of a novel strategy of anticancer therapy targeting tumor vessels instead of cancer cells. Antiangiogenic therapy aims to inhibit the growth of tumor, and current evidence suggests that it works best in combination with conventional cytotoxic chemotherapy. Recently, a monoclonal antibody against vascular endothelial growth factor, which is one of the most potent angiogenic factors, has been approved for clinical use in colorectal cancer patients after a clinical trial confirmed that combining the antibody with standard chemotherapy regimen could prolong patient survival. The clinical implications of angiogenesis in cancer are reviewed in this article.  (+info)

Stimulation of angiostatic platelet factor-4 variant (CXCL4L1/PF-4var) versus inhibition of angiogenic granulocyte chemotactic protein-2 (CXCL6/GCP-2) in normal and tumoral mesenchymal cells. (8/25)

Chemokines affect inflammation and cancer through leukocyte attraction and angiogenesis. Here, we demonstrate that CXCL4L1/platelet factor-4 variant (PF-4var), a highly angiostatic chemokine, is poorly chemotactic for phagocytes and is inducible in monocytes by inflammatory mediators but remained undetectable in macrophages and neutrophils. In addition, CXCL4L1/PF-4var production by mesenchymal tumor cells was evidenced in vitro and in vivo by specific ELISA and immunohistochemistry. CXCL4L1/PF-4var, but not CXCL4/PF-4, was coinduced with the angiogenic chemokine CXCL6/granulocyte chemotactic protein-2 (GCP-2) by cytokines, e.g., IL-1beta and IL-17, in sarcoma cells, but not in diploid fibroblasts. Furthermore, the induction of CXCL6/GCP-2 in endothelial cells by IL-1beta was enhanced synergistically by TNF-alpha but inhibited by IFN-gamma, which synergized with IL-1beta to produce the angiostatic CXCL10/IFN-gamma-induced protein-10. These findings indicate that the equilibrium between angiostatic and angiogenic factors during inflammation and tumor progression is rather complex and differs depending on the chemokine, cell type, and stimulus. Selective intervention in the chemokine network may drastically disturb this delicate balance of angiogenesis and tissue repair. Application of angiostatic CXCL4L1/PF-4var without attraction of protumoral phagocytes may be beneficial in cancer therapy.  (+info)

*Yihai Cao

He discovered several angiostatic proteins for potential treatment of cancer. Cao´s laboratory discovered catechins in green ...

*List of MeSH codes (D12.644)

... angiostatic proteins MeSH D12.644.276.100.450.500 --- angiostatins MeSH D12.644.276.100.450.750 --- endostatins MeSH D12.644. ... rap gtp-binding proteins MeSH D12.644.360.525.475.100 --- rap1 gtp-binding proteins MeSH D12.644.360.525.500 --- ras proteins ... grb2 adaptor protein MeSH D12.644.360.024.298 --- grb7 adaptor protein MeSH D12.644.360.024.300 --- grb10 adaptor protein MeSH ... 14-3-3 proteins MeSH D12.644.360.024.318 --- proto-oncogene proteins c-crk MeSH D12.644.360.024.326 --- proto-oncogene proteins ...

*List of MeSH codes (D23)

... angiostatic proteins MeSH D23.348.479.311.200.500 --- angiostatins MeSH D23.348.479.311.200.750 --- endostatins MeSH D23.348. ... hiv core protein p24 MeSH D23.050.327.520.330 --- hiv envelope protein gp41 MeSH D23.050.327.520.350 --- hiv envelope protein ... adenovirus e1 proteins MeSH D23.050.327.045.060 --- adenovirus e2 proteins MeSH D23.050.327.045.070 --- adenovirus e3 proteins ... ldl-receptor related protein 2 MeSH D23.050.422.500.750 --- ldl-receptor related protein-associated protein MeSH D23.050. ...

*Gene therapy of the human retina

When mutations occur in the rhodopsin the directional protein movement is affected because the mutations can affect protein ... Many angiostatic factors have been shown to counteract the effect of increasing local VEGF. The naturally occurring form of ... The protein RPE65 is used in the retinoid cycle where the all-trans-retinol within the rod outer segment is isomerized to its ... The opsin proteins are made in the photoreceptor inner segments, then transported to the outer segment, and eventually ...

*15-Hydroxyeicosatetraenoic acid

They may use a similar "protein-adduction" mechanism; if so the target protein(s) for these effects have not been defined or ... HPETE is angiostatic and 15(S)-HETE is angiogenic". Inflammation Research. 61 (7): 707-18. doi:10.1007/s00011-012-0463-5. PMID ... 15-hydroxyeicosatetraenoic acid promotes hepatocellular cancer cells growth through protein kinase B and heat shock protein 90 ... Wang, Y; Liang, D; Wang, S; Qiu, Z; Chu, X; Chen, S; Li, L; Nie, X; Zhang, R; Wang, Z; Zhu, D (2010). "Role of the G-protein ...

*Perlecan

This is not evidence that MMP-2 and MMP-9 directly cleave perlecan protein in vivo but shows that the proteins clearly modulate ... the angiostatic C-terminal fragment of perlecan". J. Biol. Chem. 280 (8): 7080-7. doi:10.1074/jbc.M409841200. PMID 15591058. ... "Fibroblast growth factor-binding protein is a novel partner for perlecan protein core". J. Biol. Chem. 276 (13): 10263-71. doi: ... Protein Kinase C is activated and perlecan message and protein are subsequently increased. In contrast, the usual ...
Reactome is pathway database which provides intuitive bioinformatics tools for the visualisation, interpretation and analysis of pathway knowledge.
Reactome is pathway database which provides intuitive bioinformatics tools for the visualisation, interpretation and analysis of pathway knowledge.
The chemokine family consists of proinflammatory cytokines, primarily involved in chemoattraction and activation of specific leukocytes in various immunoinflammatory responses.1-4 In addition, chemokines activate blood platelets, important components of hemostasis, contributing to wound healing by forming thrombi and to the initiation of repair processes.5 However, a recent study indicated that circulating activated platelets and platelet-leukocyte aggregates promote formation of atherosclerotic lesions.6 Finally, chemokines influence tumor growth by regulating angiogenesis. Net angiogenesis is determined by a balance between angiogenic and angiostatic factors within the local microenvironment. The CXC chemokine family is unique because it comprises angiogenic and angiostatic chemokines.7-9. The first chemokine described as a regulator of angiogenesis is platelet factor-4 (PF-4)/CXCL4.10 Although this angiostatic platelet-derived chemokine has been the subject of extensive research as a ...
Circulating 38-kDa proteins that are internal peptide fragments of PLASMINOGEN. The name derives from the fact that they are potent ANGIOGENESIS INHIBITORS. Angiostatins contain four KRINGLE DOMAINS which are associated with their potent angiostatic activity ...
Abstract Introduction: The role of platelet activation in allergic inflammation is receiving increasing attention. Sublingual immunotherapy for allergic rhinitis can modify the immunological process to an allergen, rather than simply treating symptoms. Objective: The aim of this study was to explore the role of platelet activation during sublingual immunotherapy in children with allergic rhinitis. Methods: Forty-two House Dust Mite - sensitized children with allergic rhinitis were enrolled and received House Dust Mite allergen extract for sublingual immunotherapy or placebo. Serum of different time points during treatment was collected and used for detection of Platelet Factor-4 and Beta-Thromboglobulin concentration by Enzyme-Linked Immuno Sorbent Assay. Results: Our data showed decreased expression of Platelet Factor-4 and Beta-Thromboglobulin protein after one years sublingual immunotherapy. In addition, the decrease of symptom scores and serum Platelet Factor-4 and Beta-Thromboglobulin protein
Berlin Germany: Chemicals that inhibit the development of new blood v...However the researchers warned that the work is still at an early sta...Endometriosis is a disease of the lining tissue of the womb. It can b...Annemiek Nap a doctor at the University Hospital Maastricht The Neth...They used four angiostatic compounds: anti-human vascular endothelial ...,Endometriosis:,Could,angiostatic,therapy,be,the,new,treatment,of,the,future?,biological,biology news articles,biology news today,latest biology news,current biology news,biology newsletters
Chemokines belong to a class of pro-inflammatory cytokines that have the ability to attract and activate leukocytes. Their name is derived from chemotactic cytokines" based on their ability to induce and mediate chemotaxis in nearby responsive cells. Formerly, they were called SIS family of cytokines, SIG family of cytokines, SCY family of cytokines, Platelet factor-4 superfamily or intercrines. Chemokines can be divided into at least four structural branches: c (chemokines, c), cc (chemokines, cc), cx3c (chemokines, cx3c), and cxc (chemokines, cxc). The classification is according to the variations in a shared cysteine motif. Chemokines may also be classified based on their functions. Homeostatic chemokines are chemokines that are responsible for basal leukocyte migration. Examples of homeostatic chemokines are CCL14, CCL19, CCL20, CCL21, CXCL12 and CXCL13. Nevertheless, some of them are not exclusive to this function. For instance, CCL20 is also associated with inflammation since it can act as ...
Chemokines (Greek -kinos, movement) are a family of small cytokines, or signaling proteins secreted by cells. Their name is derived from their ability to induce directed chemotaxis in nearby responsive cells; they are chemotactic cytokines. Cytokine proteins are classified as chemokines according to behavior and structural characteristics. In addition to being known for mediating chemotaxis, chemokines are all approximately 8-10 kilodaltons in mass and have four cysteine residues in conserved locations that are key to forming their 3-dimensional shape. These proteins have historically been known under several other names including the SIS family of cytokines, SIG family of cytokines, SCY family of cytokines, Platelet factor-4 superfamily or intercrines. Some chemokines are considered pro-inflammatory and can be induced during an immune response to recruit cells of the immune system to a site of infection, while others are considered homeostatic and are involved in controlling the migration of ...
Cancer cells are often dependent on epigenetic pathways for their survival. Consequently, drugs that target the epigenome, rather than the underlying DNA sequence, are currently attracting considerabl
In the Mouse Antithrombotic Assay aspirin (30-300 mg/kg) protected mice from death by 15 and 42%, respectively. Four Ca++ channel blockers (nitrendipine, nicardipine, nifedipine and verapamil) were effective in reducing the mortality. At the dose of 100 mg/kg nitrendipine and nicardipine gave 80 and 85% protection respectively. Whereas aspirin almost suppressed completely thromboxane (Tx)B2 and platelet factor-4 release after collagen-epinephrine infusion, neither nitrendipine nor nicardipine modified TxB2 release and only reduced slightly platelet factor-4 release. The treatment with aspirin, nitrendipine or nicardipine did not counteract the fall in circulating platelets counted 1 min after the aggregation challenge, but at 3 min platelet count was significantly higher in aspirin-treated mice than in animals given either Ca++ channel blocker. Mouse platelet aggregation induced in vitro by the combination of collagen and epinephrine was inhibited in samples obtained from mice pretreated with ...
To examine whether the lack of sufficient neoangiogenesis in systemic sclerosis (SSc) is caused by a decrease in angiogenic factors and/or an increase in angiostatic factors, the potent proangiogenic molecules vascular endothelial growth factor (VEGF) and basic fibroblast growth factor, and the angiostatic factor endostatin were determined in patients with SSc and in healthy controls. Forty-three patients with established SSc and nine patients with pre-SSc were included in the study. Serum levels of VEGF, basic fibroblast growth factor and endostatin were measured by ELISA. Age-matched and sex-matched healthy volunteers were used as controls. Highly significant differences were found in serum levels of VEGF between SSc patients and healthy controls, whereas no differences could be detected for endostatin and basic fibroblast growth factor. Significantly higher levels of VEGF were detected in patients with Scl-70 autoantibodies and in patients with diffuse SSc. Patients with pre-SSc and short ...
Are you hearing the buzz about CBE more and more? Its actually nothing new - some trailblazing higher education institutions have been doing this for years. But its garnered quite a bit more attention in the last few years, partially because we now have the technology to do it and track it much better, and…
Neutrophil-activating protein-2 (NAP-2) is a 72 residue protein demonstrating a range of proinflammatory activities. The solution structure of monomeric NAP-2 has been investigated by two-dimensional 1H-n.m.r. spectroscopy. Sequence-specific proton resonance assignments have been made and secondary structural elements have been identified on the basis of nuclear Overhauser data, coupling constants and amide hydrogen/deuteron exchange. The NAP-2 monomer consists of a triple-stranded anti-parallel beta-sheet arranged in a Greek key and a C-terminal helix (residues 59-70) and is very similar to that found in the n.m.r. solution conformation of dimeric interleukin-8 and the crystal structure of tetrameric bovine platelet factor-4. Results are discussed in terms of heparin binding and neutrophil-activation properties of NAP-2. ...
The purpose of this study is to evaluate the efficacy, tolerability and safety of a multi-targeted therapy in patients with hormone-refractory prostate
Introduction. Sublingual immunotherapy (SLIT) is the only treatment that regulates the immunological process during development of allergic rhinitis (AR), rather than simply treating symptoms.1,2 However, the underlying mechanisms in the process and potential biomarkers are still not fully characterized.. Platelet activation occurs during antigen-induced airway reactions in allergic and asthmatic subjects. Raised levels of platelet-derived mediators, such as the chemokines, Beta-Thromboglobulin (BTG) and Platelet Factor-4 (PF4), are observed in plasma and bronchoalveolar lavage fluid of atopic individuals. These mediators have the ability to activate eosinophils, increase expression of Fc-IgG and Fc-IgE receptors, and stimulate basophils to release histamine.3-6 Since SLIT can inhibit allergic inflammation significantly, we postulate that SLIT may affect platelet activation in AR children.. In the current study, we aimed to clarify the effect of SLIT on platelet activation of AR children by ...
Applying Multi-Scale, Multi-Cell Modeling of Pathological Neovascularization in the Retina and Solid Tumors to Suggest Novel Treatment Strategies by James Glazier Indiana University Biocomplexity Institute
Multivariate normal distribution theory, correlation and dependence analysis, regression and prediction, dimension-reduction methods, sampling distributions and related inference problems, selected applications in classification theory, multivariate process control, and pattern recognition.. ...
Platelet factor 4 (PF4) is a small cytokine belonging to the CXC chemokine family that is also known as chemokine (C-X-C motif) ligand 4 (CXCL4) . This chemokine is released from alpha-granules of activated platelets during platelet aggregation, and promotes blood coagulation by moderating the effects of heparin-like molecules. Due to these roles, it is predicted to play a role in wound repair and inflammation. It is usually found in a complex with proteoglycan. The gene for human PF4 is located on human chromosome 4. Platelet factor-4 is a 70-amino acid protein that is released from the alpha-granules of activated platelets and binds with high affinity to heparin. Its major physiologic role appears to be neutralization of heparin-like molecules on the endothelial surface of blood vessels, thereby inhibiting local antithrombin III activity and promoting coagulation. As a strong chemoattractant for neutrophils and fibroblasts, PF4 probably has a role in inflammation and wound repair. PF4 is ...
Background & Aims: It is more important to know which of physical activities could be the most effective way to cause angiogenesis. In this regards, we have investigated an 8-week aerobic training on vascular endothelial growth factor (VEGF) and Endostatin (ES) in sedentary women. Materials & Methods: 20 volunteer inactive women ...
Dr. Maniscalco studies pulmonary microvascular development in lung injury. Using various animal models, including a non-human primate model of BPD, this work examines the effects of oxygen and ventilation of immature lung on the development of alveolar capillaries. The major goals of the research are to characterize microvascular development in lung injury and investigate angiogenic and angiostatic regulators in normal and injured lung. Recent work has linked expression of inflammatory CXC chemokine mediators, which regulate angiogenesis and are part of the pathophysiology of BPD, to impaired lung microangiogenesis. ...
Dr. Maniscalco studies pulmonary microvascular development in lung injury. Using various animal models, including a non-human primate model of BPD, this work examines the effects of oxygen and ventilation of immature lung on the development of alveolar capillaries. The major goals of the research are to characterize microvascular development in lung injury and investigate angiogenic and angiostatic regulators in normal and injured lung. Recent work has linked expression of inflammatory CXC chemokine mediators, which regulate angiogenesis and are part of the pathophysiology of BPD, to impaired lung microangiogenesis. ...
This issue contains an important contribution from the team of Douglas Lauffenburger, Chair of the Editorial Board, at MIT, USA, in which they demonstrate the ability to characterise quantitative data on phenotypic behaviour of individual endothelial cells in response to angiogenesis signalling and relate it to overall population behaviour. They show that the behaviour of microvascular endothelial cells in a single population is heterogeneous and cannot be assumed to be the same for all cells in a given condition.. Endothelial cell phenotypic behaviors cluster into dynamic state transition programs modulated by angiogenic and angiostatic ...
microRNA-21 (miR-21) is the most commonly upregulated miRNA in solid tumors. This cancer-associated microRNA (oncomiR) regulates various downstream effectors associated with tumor pathogenesis during all stages of carcinogenesis. In this study, we analyzed the function of miR-21 in noncancer cells of the tumor microenvironment to further evaluate its contribution to tumor progression. We report that the expression of miR-21 in cells of the tumor immune infiltrate, and in particular in macrophages, was responsible for promoting tumor growth. Absence of miR-21 expression in tumor- associated macrophages (TAMs), caused a global rewiring of their transcriptional regulatory network that was skewed toward a proinflammatory angiostatic phenotype. This promoted an antitumoral immune response characterized by a macrophage-mediated improvement of cytotoxic T-cell responses through the induction of cytokines and chemokines, including IL-12 and C-X-C motif chemokine 10. These effects translated to a ...
LAA037Ra71, Biotin-Linked Polyclonal Antibody to Fibronectin (FN), 纤连蛋白(FN)多克隆抗体(生物素标记), FN1; CIG; FINC; LETS; MSF; GFND2; Anastellin; Migration-Stimulating Factor; Cold-Insoluble Globulin; Large, External, Transformation-Sensitive Protein | 仅供体外研究使用,不用于临床诊断!请索取进口关税税单及报关单!
RPA037Bo01, Recombinant Fibronectin (FN), 纤连蛋白(FN)重组蛋白, FN1; CIG; FINC; LETS; MSF; GFND2; Anastellin; Migration-Stimulating Factor; Cold-Insoluble Globulin; Large, External, Transformation-Sensitive Protein | 仅供体外研究使用,不用于临床诊断!请索取进口关税税单及报关单!
Treatment of patients with the VEGFR TKIs sorafenib and sunitinib can lead to periods of tumor stability, but resistance to therapy is inevitable. We used a mouse model to define mechanisms by which resistance develops and found that components of the IFNγ signaling pathway are lost with sunitinib or sorafenib therapy. Our data also show that CXCL9 treatment delays resistance to sunitinib in 786-O- and A498-derived tumors and that one mechanism by which this occurs is by prolongation of the antiangiogenic effects of sunitinib. These data suggest that angiostatic pathways are suppressed as a result of VEGFR TKI therapy and set the stage for the subsequent development of resistance to therapy.. In the setting of VEGFR inhibition, RCC tumors undergo extensive necrosis (22). In the setting of this necrosis and accompanying hypoxia/nutrient deprivation, tumors may undergo compensatory changes, including the induction of salvage angiogenesis pathways. We propose that the environmental stress ...
Treatment of metastatic renal cell cancer (RCC) with antiangiogenic agents that block vascular endothelial growth factor (VEGF) receptor 2 signaling produces tumor regression in a substantial fraction of patients; however resistance typically develops within 6-12 months. The purpose of this study was to identify molecular pathways involved in resistance. Treatment of mice bearing either 786-0 or A498 human RCC xenografts with sorafenib or sunitinib produced tumor growth stabilization followed by regrowth despite continued drug administration analogous to the clinical experience. Tumors and plasma were harvested at day 3 of therapy and at the time of resistance to assess pathways that may be involved in resistance. Serial perfusion imaging, and plasma and tumor collections were obtained in mice treated with either placebo or sunitinib alone or in combination with intratumoral injections of the angiostatic chemokine CXCL9. Sunitinib administration led to an early down-modulation of interferon ...

Treatment of Patients With Age-Related Macular Degeneration With Anecortave Acetate - Full Text View - ClinicalTrials.govTreatment of Patients With Age-Related Macular Degeneration With Anecortave Acetate - Full Text View - ClinicalTrials.gov

One new angiostatic steroid, anecortave acetate (AL-3789), may represent a breakthrough in the therapy of ocular neovascular ... Conventional laser photocoagulation of CNV requires laser intensities adequate to coagulate proteins in the target tissue. Due ... Recently, a new class of compounds (angiostatic steroids) have been found to inhibit the formation of new blood vessels (i.e. ... Unlike some of the angiostatic steroids, anecortave acetate appears to be lacking in the pharmacological activities typical of ...
more infohttps://clinicaltrials.gov/ct2/show/NCT00349739?term=eye+diseases+AND+university+of+iowa&no_unk=Y&rank=4

The Efficacy and Safety of Endostar Combined With Taxane-based Regimens for HER-2-negative MBC PatientsThe Efficacy and Safety of Endostar Combined With Taxane-based Regimens for HER-2-negative MBC Patients

Angiostatic Proteins. Proteins that specifically inhibit the growth of new blood vessels (ANGIOGENESIS, PHYSIOLOGIC). ... Angiogenic Proteins. Intercellular signaling peptides and proteins that regulate the proliferation of new blood vessels under ... This is accomplished by endogenous ANGIOGENIC PROTEINS and a variety of other chemicals and pharmaceutical agents. ... normal physiological conditions (ANGIOGENESIS, PHYSIOLOGICAL). Aberrant expression of angiogenic proteins during disease states ...
more infohttps://www.bioportfolio.com/resources/trial/163943/The-Efficacy-and-Safety-of-Endostar-Combined-With-Taxane-based-Regimens-for.html

Patente US7169904 - Immunocytokine sequences and uses thereof - Google PatentesPatente US7169904 - Immunocytokine sequences and uses thereof - Google Patentes

Methods of expressing angiostatic protein. US5886178. 28 May 1997. 23 Mar 1999. Syntex (U.S.A.) Inc.. 3-aroylbenzylpyridazinone ... Arenberg et al., (1996), "Interferon-gamma-inducible Protein 10 (IP-10) is an Angiostatic Factor that Inhibits Human Non-small ... IL-7 fusion proteins. US7465447. 30 Dic 2004. 16 Dic 2008. Merck Patent Gmbh. Fc-erythropoietin fusion protein with improved ... Once expressed, the proteins of the invention can be harvested by standard protein purification procedures (see, e.g., U.S. Pat ...
more infohttp://www.google.es/patents/US7169904?dq=flatulence

Critical Reviews™ in Eukaryotic Gene Expression - Том 11, 2001 Выпуск 4 - Begell House Digital LibraryCritical Reviews™ in Eukaryotic Gene Expression - Том 11, 2001 Выпуск 4 - Begell House Digital Library

Angiostatic Proteins and Peptides Jessica C. A. Bouma-ter Steege, Kevin H. Mayo, Arjan W. Griffioen 16 pages DOI: 10.1615/ ...
more infohttp://dl.begellhouse.com/ru/journals/6dbf508d3b17c437,402b304e20ec7424.html

Critical Reviews™ in Eukaryotic Gene Expression - Volume 11, 2001 Edição 4 - Begell House Digital LibraryCritical Reviews™ in Eukaryotic Gene Expression - Volume 11, 2001 Edição 4 - Begell House Digital Library

Angiostatic Proteins and Peptides Jessica C. A. Bouma-ter Steege, Kevin H. Mayo, Arjan W. Griffioen 16 pages DOI: 10.1615/ ...
more infohttp://dl.begellhouse.com/pt/journals/6dbf508d3b17c437,402b304e20ec7424.html

Critical Reviews™ in Eukaryotic Gene Expression - Volume 11, 2001 Issue 4 - Begell House Digital LibraryCritical Reviews™ in Eukaryotic Gene Expression - Volume 11, 2001 Issue 4 - Begell House Digital Library

Angiostatic Proteins and Peptides Jessica C. A. Bouma-ter Steege, Kevin H. Mayo, Arjan W. Griffioen 16 pages DOI: 10.1615/ ...
more infohttp://www.dl.begellhouse.com/journals/6dbf508d3b17c437,402b304e20ec7424.html

Yihai Cao - WikipediaYihai Cao - Wikipedia

He discovered several angiostatic proteins for potential treatment of cancer. Cao´s laboratory discovered catechins in green ...
more infohttps://en.wikipedia.org/wiki/Yihai_Cao

CNS Malignancy Clinical Research | OSUCCC - JamesCNS Malignancy Clinical Research | OSUCCC - James

Researchers now propose to elucidate the role of this angiostatic protein in viral propagation, glioma biology and OV efficacy. ... HMGB1 is normally a cellular protein that is released into the extracellular environment upon certain stimuli and can serve as ... Objective: to examine the role of a newly-identified protein called PKM2 in mediating radiation resistance in glioblastoma. ... Objective: to examine the role of a newly-identified protein called PKM2 in mediating radiation resistance in glioblastoma. ...
more infohttps://cancer.osu.edu/research-and-education/clinical-research/cns-malignancy

ORBi: Browsing ORBiORBi: Browsing ORBi

The Angiostatic Protein 16K Human Prolactin Significantly Prevents Tumor-Induced Lymphangiogenesis by Affecting Lymphatic ... These protein-chips allow to identify multiple proteins from small amounts of samples within a single experiment. Three ... The 16-kDa angiostatic N-terminal fragment of human prolactin (16K hPRL) has been reported to be a new potent anticancer ... The 16-kDa angiostatic N-terminal fragment of human prolactin (16K hPRL) has been reported to be a new potent anticancer ...
more infohttp://orbi.ulg.ac.be/browse?type=author&value=Lion,%20Michelle%20p001937

Critical role of indoleamine 2,3-dioxygenase in tumor resistance to repeated treatments with targeted IFNγ | Molecular Cancer...Critical role of indoleamine 2,3-dioxygenase in tumor resistance to repeated treatments with targeted IFNγ | Molecular Cancer...

... an angiostatic protein (8, 13), and can inhibit tumor angiogenesis (3, 13, 14). Because of these effects, IFNγ can activate ... Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo. J Exp Med 1995;182:155-62. ... Although the therapeutic efficacy of this protein (called IFNγ-NGR) in animal models is greater than that of IFNγ, frequent ... The immunomodulatory, antiproliferative, and angiostatic activities of IFNγ make this cytokine an attractive anticancer agent ( ...
more infohttp://mct.aacrjournals.org/content/7/12/3859.long

POLYMERIC COMPOSITIONS AND METHODS OF MAKING AND USING THEREOF - Patent applicationPOLYMERIC COMPOSITIONS AND METHODS OF MAKING AND USING THEREOF - Patent application

... of expressing angiostatic protein;" 5,861,372 for "Aggregate angiostatin and method of use;" 5,854,221 for "Endothelial cell ... The protein can also be mixtures of proteins, where one or more of the proteins are modified. Specific examples of proteins ... extracellular matrix protein, or a partially hydrolyzed derivative of an extracellular matrix protein. The proteins can be ... Proteins useful in the methods described herein include, but are not limited to, an extracellular matrix protein, a chemically- ...
more infohttp://www.patentsencyclopedia.com/app/20130129797

Ocular Tolerance of an Eiav Based Lentiviral Vector Treatment for Neovascular Age-Related Macular Degeneration (Retinostat®) in...Ocular Tolerance of an Eiav Based Lentiviral Vector Treatment for Neovascular Age-Related Macular Degeneration (Retinostat®) in...

... for the treatment of wet-AMD that is designed to express the potent angiostatic proteins endostatin (End) and angiostatin (Ang ... under the constitutive CMV promoter and the retinal pigment epithelial cell specific VMD2 promoter demonstrated greater protein ...
more infohttps://iovs.arvojournals.org/article.aspx?articleid=2371746

Is Angiostatin Involved in Physiological Foveal Avascularity? | IOVS | ARVO JournalsIs Angiostatin Involved in Physiological Foveal Avascularity? | IOVS | ARVO Journals

8 expression of several angiostatic proteins including ephrins A1 and A4 and their receptor EphA6, brain natriuretic peptide ( ... Calnexin (90 kDa) expression verified the amount of protein loaded per lane. Protein bands are labeled in kDa. (L-N) Integrin ... Calnexin (90 kDa) expression verified the amount of protein loaded per lane. Protein bands are labeled in kDa. (L-N) Integrin ... Calnexin (90 kDa) expression verified the amount of protein loaded per lane. Protein bands are labeled in kDa. (L-N) Integrin ...
more infohttps://iovs.arvojournals.org/article.aspx?articleid=2549975

Protocols and Video Articles Authored by Joey P. GrangerProtocols and Video Articles Authored by Joey P. Granger

... downregulates the angiostatic protein soluble fms-like tyrosine kinase 1 from placental villous explants and that the HO-1 ... The contracting factors could also increase the activity of vascular protein kinases such as protein kinase C, leading to ... The untreated Dahl S rats had a significant rise in blood pressure and a 2-fold increase in urinary protein excretion from ... Here, we have investigated the role of adenosine in the secretion of VEGF and the antiangiogenic protein sFlt-1 in placental ...
more infohttps://www.jove.com/author/Joey+P._Granger

DeCS Ingl s+escopoDeCS Ingl s+escopo

D23.529.100 Angiogenic Proteins .. D23.529.100.450 Angiostatic Proteins .. D23.529.100.450.500 Angiostatins .. E01 Diagnosis . ... D12.776.467.100 Angiogenic Proteins .. D12.776.467.100.450 Angiostatic Proteins .. D12.776.467.100.450.500 Angiostatins .. D23 ... D12.644.276.100.450 Angiostatic Proteins .. D12.644.276.100.450.500 Angiostatins .. D12.776 Proteins .. D12.776.124 Blood ... D12 Amino Acids, Peptides, and Proteins .. D12.644 Peptides .. D12.644.276 Intercellular Signaling Peptides and Proteins .. ...
more infohttp://trigramas.bireme.br/cgi-bin/mx/[email protected]?collection=DeCSxi&lang=i&minsim=0.30&maxrel=10&text=Angiosperma

Serum vascular endothelial growth factor as a marker of asthma exacerbationSerum vascular endothelial growth factor as a marker of asthma exacerbation

... which is regulated by a balance of proangiogenic growth factors and angiostatic proteins. However, during chronic inflammation ...
more infohttp://www.kjim.org/journal/view.php?number=169810

5 Eye Exercises to Heal and Reverse Eye Problems5 Eye Exercises to Heal and Reverse Eye Problems

Encoding angiostatic proteins and siRNA against VEGF and VEGF receptors has been demonstrated in ocular neovascularization 67- ... prevent essential protein-protein interactions that maintain lens transparency, and or decrease solubility that results in the ... These proteins are components of the cone pho-totransduction cascade, and, as a result of mutations, signals are not generated ... The cloudy area worsens as protein fibers in the lens clump together, preventing light rays from passing through the lens and ...
more infohttps://www.americorpshealth.biz/eye-problems.html

Ophthalmologist Bates Cures Unclear Eyesight - AmeriCorps Health BlogOphthalmologist Bates Cures Unclear Eyesight - AmeriCorps Health Blog

Encoding angiostatic proteins and siRNA against VEGF and VEGF receptors has been demonstrated in ocular neovascularization 67- ... prevent essential protein-protein interactions that maintain lens transparency, and or decrease solubility that results in the ... These proteins are components of the cone pho-totransduction cascade, and, as a result of mutations, signals are not generated ... The cloudy area worsens as protein fibers in the lens clump together, preventing light rays from passing through the lens and ...
more infohttps://www.americorpshealth.biz/ophthalmologist.html

List of MeSH codes (D12.644) - WikipediaList of MeSH codes (D12.644) - Wikipedia

... angiostatic proteins MeSH D12.644.276.100.450.500 --- angiostatins MeSH D12.644.276.100.450.750 --- endostatins MeSH D12.644. ... rap gtp-binding proteins MeSH D12.644.360.525.475.100 --- rap1 gtp-binding proteins MeSH D12.644.360.525.500 --- ras proteins ... grb2 adaptor protein MeSH D12.644.360.024.298 --- grb7 adaptor protein MeSH D12.644.360.024.300 --- grb10 adaptor protein MeSH ... 14-3-3 proteins MeSH D12.644.360.024.318 --- proto-oncogene proteins c-crk MeSH D12.644.360.024.326 --- proto-oncogene proteins ...
more infohttps://en.wikipedia.org/wiki/List_of_MeSH_codes_(D12.644)

Sprouty1, a new target of the angiostatic agent 16K prolactin, negatively regulates angiogenesis | Molecular Cancer | Full TextSprouty1, a new target of the angiostatic agent 16K prolactin, negatively regulates angiogenesis | Molecular Cancer | Full Text

... and adhesion to extracellular matrix proteins. SPRY1 knockdown was also shown to affect the expression of cyclinD1 and p21 both ... SPRY1 by comparing the transcriptomes of untreated endothelial cells with those of endothelial cells treated by the angiostatic ... Total protein was extracted from these cells and the level of phospho-Erk1/2 protein was measured by Western blotting. The ... SPRY1 protein expression analyzed by Western blotting on total protein extracted from ABAE cells treated for 1 to 6 hours with ...
more infohttps://molecular-cancer.biomedcentral.com/articles/10.1186/1476-4598-9-231

Evidence for annexin II-S100A10 complex and plasmin in mobilization of cytokine activity of human TrpRS. - Radcliffe Department...Evidence for annexin II-S100A10 complex and plasmin in mobilization of cytokine activity of human TrpRS. - Radcliffe Department...

Thus, complexes of mammalian tRNA synthetases with seemingly disparate proteins may in general be relevant to understanding how ... and a similar natural proteolytic fragment are potent angiostatic factors that act through the vascular endothelial-cadherin ... Little is known about these interactions and how they facilitate expanded functions that link protein translation to other ... Protein Biosynthesis, Protein Transport, Proto-Oncogene Proteins c-akt, S100 Proteins, Signal Transduction, Tryptophan-tRNA ...
more infohttps://www.rdm.ox.ac.uk/publications/559547

Enhancing Viral Oncolysis with Vasculostatin Gene Delivery - Balveen KaurEnhancing Viral Oncolysis with Vasculostatin Gene Delivery - Balveen Kaur

We now propose to elucidate the role of this angiostatic protein in viral propagation, glioma biology and OV efficacy. ... Characterizing Isu Scaffolding Protein and ISC Multiprotein Complex Structure and. *Mechanisms of action of PTH1 ligands on the ... Regulation of heterotrimeric G proteins by non-receptor activators. *Regulation of bacterial polysaccharide-specific B cell ...
more infohttp://grantome.com/grant/NIH/R01-CA150153-04

Angiopoietin-2 concentration in serum is associated with severe asthma phenotype | Allergy, Asthma & Clinical Immunology | Full...Angiopoietin-2 concentration in serum is associated with severe asthma phenotype | Allergy, Asthma & Clinical Immunology | Full...

... are poorly understood but seem to be regulated by the balance between proangiogenic growth factors and angiostatic proteins [11 ... Eosinophil cationic protein (ECP) were measured in serum with ImmunoCAP system (Pharmacia diagnostic, Sweden). ...
more infohttps://aacijournal.biomedcentral.com/articles/10.1186/s13223-016-0112-6

Patent US7601814 - Reducing the immunogenicity of fusion proteins - Google PatentsPatent US7601814 - Reducing the immunogenicity of fusion proteins - Google Patents

Fusion proteins of the invention include a junction region having an amino acid change that reduces the ability of a junctional ... or modifying one or more amino acids in the junction region of a fusion protein in order to identify a T-cell epitope and ... Disclosed are compositions and methods for producing fusion proteins with reduced immunogenicity. ... Methods of expressing angiostatic protein. US5886178. 28 May 1997. 23 Mar 1999. Syntex (U.S.A.) Inc.. 3-aroylbenzylpyridazinone ...
more infohttp://www.google.ca/patents/US7601814

Strain variation in response to lung ischemia: role of MMP-12 | Respiratory Research | Full TextStrain variation in response to lung ischemia: role of MMP-12 | Respiratory Research | Full Text

... key matrix proteins have not been identified. Since the degradation of chemokines has been shown to be dependent on ... However, the proteins that orchestrate the complex interaction of new vessel growth and tunneling through lung tissue matrix ... metalloproteinases (MMP), we first surveyed gene expression patterns (real time RT-PCR) of several lung matrix proteins in DBA/ ... we speculated in a second series of experiments that increased MMP-12 activity contributed directly to an angiostatic protein ...
more infohttps://0-respiratory--research-biomedcentral-com.brum.beds.ac.uk/articles/10.1186/1465-9921-13-93
  • One new angiostatic steroid, anecortave acetate (AL-3789), may represent a breakthrough in the therapy of ocular neovascular diseases such as AMD and diabetic retinopathy. (clinicaltrials.gov)
  • Unlike some of the angiostatic steroids, anecortave acetate appears to be lacking in the pharmacological activities typical of the steroid family (i.e. glucocorticoid, anti-inflammatory, cardiovascular, neurologic, diuretic, etc. (clinicaltrials.gov)
  • Retinas of newborn, juvenile, and adult Callithrix jacchus and Macaca fascicularis monkeys and control human retinas were studied to determine the localization of angiostatin relative to III β-tubulin, glial fibrillary acidic protein, vascular endothelial growth factor (VEGF), platelet endothelial cell adhesion molecule-1 (PECAM), and the angiostatin receptor αvβ3-integrin in the foveal, macular, and peripheral retina. (arvojournals.org)
  • Essential to most RTK-mediated signaling is the activation of the extracellular-signal-regulated kinase/mitogen-activated protein kinase (ERK/MAPK) signaling cascade. (biomedcentral.com)
  • Fc gamma R-dependent mitogen-activated protein kinase activation in leukocytes: a common signal transduction event necessary for expression of TNF-alpha and early activation genes. (rupress.org)
  • Thus, complexes of mammalian tRNA synthetases with seemingly disparate proteins may in general be relevant to understanding how their expanded functions are implemented. (ox.ac.uk)
  • Isoform 2, T1-TrpRS and T2-TrpRS possess angiostatic activity whereas isoform 1 lacks it. (abcam.com)
  • Residues 12-65 of the NH 2 -terminal extension of human TrpRS are homologous to the WHEP-TRP conserved domain protein family (pfam00458) ( 8 ). (pnas.org)
  • the major form is the full-length protein, and the other is a truncated TrpRS (mini TrpRS) in which most of the extra NH 2 -terminal domain is deleted because of alternative splicing of the pre-mRNA ( 16 , 17 ), with Met-48 being deduced as the NH 2 -terminal residue of mini TrpRS ( 16 ). (pnas.org)
  • Thus, GD2 is a convenient tumor-specific marker for targeting immune-stimulatory protein domains to tumor cells for the purpose of raising an effective immune response against the tumor cells to destroy them. (google.es)
  • Fusion proteins of the invention include a junction region having an amino acid change that reduces the ability of a junctional epitope to bind to MHC Class II, thereby reducing its interaction with a T-cell. (google.ca)
  • Methods of the invention involve analyzing, changing, or modifying one or more amino acids in the junction region of a fusion protein in order to identify a T-cell epitope and reduce its ability to interact with a T cell receptor. (google.ca)
  • More specifically, the invention relates to fusion proteins, made less immunogenic by identifying candidate T-cell epitopes and modifying the amino acid sequence to eliminate such epitopes. (google.ca)
  • Comparisons of End and Ang under the constitutive CMV promoter and the retinal pigment epithelial cell specific VMD2 promoter demonstrated greater protein production with the CMV promoter in both the retina and vitreous. (arvojournals.org)
  • However, the proteins that orchestrate the complex interaction of new vessel growth and tunneling through lung tissue matrix have not been described. (beds.ac.uk)
  • Little is known about these interactions and how they facilitate expanded functions that link protein translation to other cellular pathways. (ox.ac.uk)
  • 3. The fusion protein of claim 1 , wherein the junction region comprises an IgG sequence having an ATAT amino acid sequence (amino acids 3-6 of SEQ ID NO:6) instead of an LSLS amino acid sequence (amino acids 3-6 of SEQ ID NO:5). (google.ca)
  • 4. The fusion protein of claim 1 , wherein the junction region comprises an IgG region wherein the LSLS amino acid sequence (amino acids 3-6 of SEQ ID NO:5) is mutated without generating a T-cell epitope. (google.ca)
  • In general, immune responses against completely normal human proteins are rare when these proteins are used as therapeutics. (google.ca)
  • Objective: to examine the role of a newly-identified protein called PKM2 in mediating radiation resistance in glioblastoma. (osu.edu)
  • They are subject to tight control at multiple levels: differential localization, post-translational modification, and regulation of protein levels. (biomedcentral.com)